Skip to Content

Generic Mulpleta Availability

Medically reviewed by Drugs.com. Last updated on May 11, 2021.

Mulpleta is a brand name of lusutrombopag, approved by the FDA in the following formulation(s):

MULPLETA (lusutrombopag - tablet;oral)

  • Manufacturer: SHIONOGI INC
    Approval date: July 31, 2018
    Strength(s): 3MG [RLD]

Has a generic version of Mulpleta been approved?

No. There is currently no therapeutically equivalent version of Mulpleta available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Mulpleta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Compounds exhibiting thrombopoietin receptor agonism
    Patent 7,601,746
    Issued: October 13, 2009
    Inventor(s): Takayama; Masami & Yoshida; Yutaka
    Assignee(s): Shionogi & Co., Ltd.

    A compound represented by the general formula (I): wherein R1 is a hydrogen atom, a halogen atom, or the like; R2, R3, and R4 are each independently a hydrogen atom, a halogen atom, C1-C15 alkyl optionally substituted with one or more C1-C12 alkyloxy or the like, or the like; R5 is a hydrogen atom or the like; R6 and R7 are a hydrogen atom or the like; R8 is C1-C3 alkyl or the like; R9 is a hydrogen atom or the like), a prodrug, a pharmaceutically acceptable salt, or solvate thereof.

    Patent expiration dates:

    • September 5, 2024
      ✓ 
      Patent use: TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC LIVER DISEASE WHO ARE SCHEDULED TO UNDERGO A PROCEDURE
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor
    Patent 8,530,668
    Issued: September 10, 2013
    Assignee(s): Shionogi & Co., Ltd.

    An optically active 4-phenylthiazole derivative having a thrombopoietin receptor agonist activity and a pharmaceutical composition containing the present compound as an active ingredient are created, and a platelet production regulating agent which can be orally administered is provided. Disclosed is a pharmaceutical composition containing, as an active ingredient, an optically active compound represented by the formula: wherein, R1 is a halogen atom or C1-C3 alkyloxy; R2 is C1-C8 alkyl; R3 is C1-C8 alkyl; R4 and R5 are each independently a fluorine atom or chlorine atom; R6 is C1-C3 alkyl or C1-C3 alkyloxy; * indicates that a carbon atom marked with an asterisk is an asymmetric carbon, a pharmaceutically acceptable salt thereof, or a solvate thereof.

    Patent expiration dates:

    • January 21, 2030
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor
    Patent 8,889,722
    Issued: November 18, 2014
    Assignee(s): Shionogi & Co., Ltd.

    An optically active 4-phenylthiazole derivative having a thrombopoietin receptor agonist activity and a pharmaceutical composition containing the present compound as an active ingredient are created, and a platelet production regulating agent which can be orally administered is provided. Disclosed is a pharmaceutical composition containing, as an active ingredient, an optically active compound represented by the formula: wherein, R1 is a halogen atom or C1-C3 alkyloxy; R2 is C1-C8 alkyl; R3 is C1-C8 alkyl; R4 and R5 are each independently a fluorine atom or chlorine atom; R6 is C1-C3 alkyl or C1-C3 alkyloxy; * indicates that a carbon atom marked with an asterisk is an asymmetric carbon, a pharmaceutically acceptable salt thereof, or a solvate thereof.

    Patent expiration dates:

    • July 29, 2028
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Preparation for improving solubility of poorly soluble drug
    Patent 9,427,402
    Issued: August 30, 2016
    Assignee(s): Shionogi & Co. Ltd.

    The present invention relates to solubility improving preparation for enhancing the oral absorption of a poorly soluble drug, which is comprising (A) and (B); (A) a granulated substance which comprises (i) a poorly soluble drug having an acidic group in the molecule, (ii) an alkaline agent, (iii) a surfactant, and this granulated substance dose not substantially contain a disintegrator, (B) a disintegrator existing only in the external of the granulated substance.

    Patent expiration dates:

    • September 29, 2031
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • July 31, 2023 - NEW CHEMICAL ENTITY

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.